<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34082475</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>19</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2249</ISSN><JournalIssue CitedMedium="Internet"><Volume>205</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Clinical and experimental immunology</Title><ISOAbbreviation>Clin Exp Immunol</ISOAbbreviation></Journal><ArticleTitle>Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2&#xa0;infection.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>105</EndPage><MedlinePgn>99-105</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/cei.13623</ELocationID><Abstract><AbstractText>Coronavirus 19 (COVID-19) has been associated with both transient and&#xa0;persistent&#xa0;systemic symptoms that do not appear to be&#xa0;a direct consequence of viral infection. The generation of autoantibodies has been proposed as a mechanism to explain these symptoms. To understand the prevalence of autoantibodies associated with severe acute respiratory syndrome coronavirus 2&#xa0;(SARS-CoV-2) infection,&#xa0;we investigated the frequency and specificity of clinically relevant autoantibodies in 84 individuals previously infected with SARS-CoV-2, suffering from COVID-19 of varying severity in both the acute and convalescent setting. These were compared with results from 32 individuals who were on the intensive therapy unit (ITU) for non-COVID reasons. We demonstrate&#xa0;a higher frequency of autoantibodies in the COVID-19 ITU group compared with non-COVID-19 ITU disease control patients&#xa0;and that autoantibodies were also found in the&#xa0;serum&#xa0;3-5 months post-COVID-19 infection.&#xa0;Non-COVID patients displayed a diverse pattern of autoantibodies; in contrast, the COVID-19 groups had a more restricted panel of autoantibodies including skin, skeletal muscle and cardiac antibodies. Our results demonstrate that respiratory viral infection with SARS-CoV-2 is associated with the detection of a limited profile of tissue-specific autoantibodies, detectable using routine clinical immunology assays. Further studies are required to determine whether these autoantibodies are specific to SARS-CoV-2 or a phenomenon arising from severe viral infections and to determine the clinical significance of these autoantibodies.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Clinical &amp; Experimental Immunology published by John Wiley &amp; Sons Ltd on behalf of British Society for Immunology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Alex G</ForeName><Initials>AG</Initials><Identifier Source="ORCID">0000-0003-2885-1299</Identifier><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shields</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karim</LastName><ForeName>Abid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birch</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faustini</LastName><ForeName>Sian E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steadman</LastName><ForeName>Lora</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Kerensa</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plant</LastName><ForeName>Timothy</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>Gary</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veenith</LastName><ForeName>Tonny</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>Adam F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drayson</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wraith</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V028448/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_20060</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0701275</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>BB/L009986/1</GrantID><Acronym>BB_</Acronym><Agency>Biotechnology and Biological Sciences Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/N023706/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Exp Immunol</MedlineTA><NlmUniqueID>0057202</NlmUniqueID><ISSNLinking>0009-9104</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="Y">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009928" MajorTopicYN="N">Organ Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Mark T. Drayson reports personal fees from Abingdon Health, outside the submitted work. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>5</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>3</Day><Hour>20</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34082475</ArticleId><ArticleId IdType="pmc">PMC8239842</ArticleId><ArticleId IdType="doi">10.1111/cei.13623</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kivity S, Agmon&#x2010;Levin N, Blank M, Shoenfeld Y. Infections and autoimmunity&#xa0;&#x2013;&#xa0;friends or foes? Trends Immunol. 2009;30:409&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">19643667</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC. Guillain&#x2010;Barr&#xe9; syndrome: The first documented COVID&#x2010;19&#x2010;triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm. 2020;7:e781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7309518</ArticleId><ArticleId IdType="pubmed">32518172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh AB, Chourasia PK, Javed N, Chourasia MK, Suriya SS, Upadhyay S, et al. Association of Guillain&#x2013;Barre syndrome with COVID&#x2010;19 infection: An updated systematic review. J Neuroimmunol. 2021;355:577577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053360</ArticleId><ArticleId IdType="pubmed">33895700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID&#x2010;19: a systematic review. SN Compr Clin Med. 2020;1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7501509</ArticleId><ArticleId IdType="pubmed">32984764</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID&#x2010;19. Ann Rheum Dis. 2020;79:1661&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi MO, Beltagy A, Garrafa E, Curreli D, Cecchini G, Bodio C, et al. Anti&#x2010;phospholipid antibodies in COVID&#x2010;19 are different from those detectable in the anti&#x2010;phospholipid syndrome. Front Immunol. 2020;11:584241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7593765</ArticleId><ArticleId IdType="pubmed">33178218</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeano&#x2010;Valle F, Oblitas CM, Ferreiro&#x2010;Maz&#xf3;n MM, Alonso&#x2010;Mu&#xf1;oz J, del Toro&#x2010;Cervera J, di Natale M, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID&#x2010;19 pneumonia and venous thromboembolism. Thromb Res. 2020;192:113&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227496</ArticleId><ArticleId IdType="pubmed">32425261</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life&#x2010;threatening COVID&#x2010;19. Science 2020;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, Dai Y, Huck JD, Liu F, et al. Diverse Functional Autoantibodies in Patients with COVID&#x2010;19. medRxiv 2020. doi: 10.1101/2020.12.10.20247205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.12.10.20247205</ArticleId><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez&#x2010;Toledo M, Faustini SE, Jossi SE, Shields AM, Kanthimathinathan HK, Allen JD, et al. Serology confirms SARS&#x2010;CoV&#x2010;2 infection in PCR&#x2010;negative children presenting with Paediatric Inflammatory Multi&#x2010;System Syndrome. medRxiv 2020. doi: 10.1101/2020.06.05.20123117.</Citation></Reference><Reference><Citation>Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The immunology of multisystem inflammatory syndrome in children with COVID&#x2010;19. Cell 2020;183:968&#x2013;81.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber CN, Patel RS, Trachtman R, Lepow L, Amanat F, Krammer F, et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS&#x2010;C). Cell 2020;183:982&#x2013;995.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreye J, Reincke SM, Pr&#xfc;ss H. Do cross&#x2010;reactive antibodies cause neuropathology in COVID&#x2010;19? Nat Rev Immunol. 2020;20:645&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7537977</ArticleId><ArticleId IdType="pubmed">33024283</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID&#x2010;19&#x2010;related death using OpenSAFELY. Nature 2020;584:430&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27:601&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandini DA, Takamiya AS, Thakkar P, Schaller S, Rahat R, Naqvi AR, et al. Covid&#x2010;19 and oral diseases: Crosstalk, synergy or association? Rev Med Virol. 2021. doi:10.1002/rmv.2226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2226</ArticleId><ArticleId IdType="pmc">PMC8014590</ArticleId><ArticleId IdType="pubmed">33646645</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekhtman S, Tannenbaum R, Strunk A, Birabaharan M, Wright S, Grbic N, et al. Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID&#x2010;19. J Am Acad Dermatol. 2021;84:946&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837130</ArticleId><ArticleId IdType="pubmed">33359476</ArticleId></ArticleIdList></Reference><Reference><Citation>Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, et al. Clinical characteristics of children and young people admitted to hospital with COVID&#x2010;19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020;370:m3249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488201</ArticleId><ArticleId IdType="pubmed">32960186</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>